The California Institute for Regenerative Medicine (CIRM) — a state agency created to advance novel treatments for serious medical…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Certain antipsychotic medications, including the Huntington’s approved therapy tetrabenazine (sold as Xenazine in the U.S., with generics available), significantly…
Complex fatty molecules called gangliosides are key to the formation of cellular shipping containers that help brain nerve cells get…
Researchers in China have developed a new system to grow the specific type of brain cells that are lost in…
Three years of treatment with Ingrezza (valbenazine) led to rapid and sustained reductions in the severity of uncontrolled movements…
Up to two years of pridopidine treatment continues to slow Huntington’s disease progression among patients not taking certain…
Available evidence does not indicate that treatments approved for people with Alzheimer’s disease can improve cognitive function in people with…
uniQure’s experimental gene therapy AMT-130 safely and effectively slows the progression of Huntington’s disease, according to top-line, three-year…
Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of…
Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements…